CITÓMICA
University of Michigan–Ann Arbor
Ann Arbor, Estados UnidosPublications in collaboration with researchers from University of Michigan–Ann Arbor (24)
2024
-
Harmonization of Diagnostic Criteria in Mastocytosis for Use in Clinical Practice: WHO vs ICC vs AIM/ECNM
Journal of Allergy and Clinical Immunology: In Practice
2023
-
Antibody-Based and Cell Therapies for Advanced Mastocytosis: Established and Novel Concepts
International Journal of Molecular Sciences, Vol. 24, Núm. 20
-
The Normal Range of Baseline Tryptase Should Be 1 to 15 ng/mL and Covers Healthy Individuals With HαT
Journal of Allergy and Clinical Immunology: In Practice, Vol. 11, Núm. 10, pp. 3010-3020
2022
-
Clinical impact and proposed application of molecular markers, genetic variants, and cytogenetic analysis in mast cell neoplasms: Status 2022
Journal of Allergy and Clinical Immunology, Vol. 149, Núm. 6, pp. 1855-1865
-
Global Classification of Mast Cell Activation Disorders: An ICD-10-CM–Adjusted Proposal of the ECNM-AIM Consortium
Journal of Allergy and Clinical Immunology: In Practice, Vol. 10, Núm. 8, pp. 1941-1950
-
Personalized Management Strategies in Mast Cell Disorders: ECNM-AIM User's Guide for Daily Clinical Practice
Journal of Allergy and Clinical Immunology: In Practice, Vol. 10, Núm. 8, pp. 1999-2012.e6
-
Proposed European Competence Network on Mastocytosis—American Initiative in Mast Cell Diseases (ECNM-AIM) Response Criteria in Advanced Systemic Mastocytosis
Journal of Allergy and Clinical Immunology: In Practice, Vol. 10, Núm. 8, pp. 2025-2038.e1
-
Refined Treatment Response Criteria for Indolent Systemic Mastocytosis Proposed by the ECNM-AIM Consortium
Journal of Allergy and Clinical Immunology: In Practice, Vol. 10, Núm. 8, pp. 2015-2024
-
Standards of Genetic Testing in the Diagnosis and Prognostication of Systemic Mastocytosis in 2022: Recommendations of the EU-US Cooperative Group
Journal of Allergy and Clinical Immunology: In Practice, Vol. 10, Núm. 8, pp. 1953-1963
-
Standards of Pathology in the Diagnosis of Systemic Mastocytosis: Recommendations of the EU-US Cooperative Group
Journal of Allergy and Clinical Immunology: In Practice, Vol. 10, Núm. 8, pp. 1986-1998.e2
2021
-
COVID-19 Vaccination in Mastocytosis: Recommendations of the European Competence Network on Mastocytosis (ECNM) and American Initiative in Mast Cell Diseases (AIM)
Journal of Allergy and Clinical Immunology: In Practice, Vol. 9, Núm. 6, pp. 2139-2144
-
COVID-19 infection in patients with mast cell disorders including mastocytosis does not impact mast cell activation symptoms
Journal of Allergy and Clinical Immunology: In Practice, Vol. 9, Núm. 5, pp. 2083-2086
-
Proceedings from the Inaugural American Initiative in Mast Cell Diseases (AIM) Investigator Conference
Journal of Allergy and Clinical Immunology
-
Selecting the Right Criteria and Proper Classification to Diagnose Mast Cell Activation Syndromes: A Critical Review
Journal of Allergy and Clinical Immunology: In Practice, Vol. 9, Núm. 11, pp. 3918-3928
-
Updated Diagnostic Criteria and Classification of Mast Cell Disorders: A Consensus Proposal
HemaSphere, Vol. 5, Núm. 11, pp. E646
2020
-
Mast cells as a unique hematopoietic lineage and cell system: From Paul Ehrlich's visions to precision medicine concepts
Theranostics, Vol. 10, Núm. 23, pp. 10743-10768
-
Risk and management of patients with mastocytosis and MCAS in the SARS-CoV-2 (COVID-19) pandemic: Expert opinions
Journal of Allergy and Clinical Immunology, Vol. 146, Núm. 2, pp. 300-306
2019
-
Guidelines for the use of flow cytometry and cell sorting in immunological studies (second edition)
European Journal of Immunology, Vol. 49, Núm. 10, pp. 1457-1973
-
Proposed Diagnostic Algorithm for Patients with Suspected Mast Cell Activation Syndrome
Journal of Allergy and Clinical Immunology: In Practice, Vol. 7, Núm. 4, pp. 1125-1133.e1
2017
-
Proposed Terminology and Classification of Pre-Malignant Neoplastic Conditions: A Consensus Proposal
EBioMedicine, Vol. 26, pp. 17-24